Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Indivior    INDV   GB00BRS65X63

INDIVIOR

(INDV)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
01/14/2021 01/15/2021 01/18/2021 01/19/2021 01/20/2021 Date
105(c) 115.3(c) 119.2(c) 129.8(c) 131.7 Last
1 400 700 5 005 768 1 122 354 1 711 831 381 327 Volume
+1.94% +9.81% +3.38% +8.89% +1.46% Change
More quotes
Financials (USD)
Sales 2020 648 M - -
Net income 2020 -104 M - -
Net cash position 2020 612 M - -
P/E ratio 2020 -10,5x
Yield 2020 -
Sales 2021 624 M - -
Net income 2021 87,9 M - -
Net cash position 2021 605 M - -
P/E ratio 2021 16,4x
Yield 2021 -
Capitalization 1 299 M 1 297 M -
EV / Sales 2020 1,06x
EV / Sales 2021 1,11x
Nbr of Employees 796
Free-Float 98,3%
More Financials
Company
Indivior specializes in the development, production and marketing of buprenorphine based medicines intended for the treatment of addiction to opiates. 78.6% of net sales are in the United States. 
More about the company
Notations Surperformance© of Indivior
Trading Rating : Investor Rating :
More Ratings
All news about INDIVIOR
01/15INDIVIOR : The Department of Health and Human Services Announces New Guidance In..
PU
01/15LONDON STOCK EXCHANGE : FTSE 100 logs worst week since October-end on lockdown w..
RE
01/15INDIVIOR : Provides Preliminary FY 2020 Financial Results Ahead of Guidance
PU
01/15INDIVIOR : raises revenue forecast as U.S. opioid treatment sales recover
RE
01/15INDIVIOR : Lifts Net Revenue Guidance for 2020, Flags Higher-than-Expected Adjus..
MT
01/12INDIVIOR : Directorate Change
PU
01/12PRESS RELEASE : Addex to Present at the Baader Helvea Swiss Equities Conference
DJ
01/11PRESS RELEASE : Addex Successfully Completes $11.5 Million Capital Increase Incl..
DJ
2020INDIVIOR : Claim filed by Reckitt Benckiser Group
PU
2020PRESS RELEASE : Addex Announces Filing of Registration Statement for Proposed Pu..
DJ
2020INDIVIOR : Statement related to a claim filed against it by Reckitt Benckiser Gr..
PU
2020UPDATE : Indivior Gains 9% as It Refutes Reckitt Benckiser's Claim Over 2014 Dem..
MT
2020INDIVIOR : to 'vigorously defend' Reckitt Benckiser's $1.4 billion claim
RE
2020INDIVIOR : Says Reckitt Benckiser's Claim is Without Merit
DJ
2020Indivior Refutes Reckitt Benckiser's Claim Over 2014 Demerger
MT
More news
News in other languages on INDIVIOR
2020Addex dämmt Verlust im Q3 ein - Pipeline-Verzögerungen wegen Covid-19
2020Aktien Schweiz Schluss: SMI fester zum Wochenstart - Finanzwerte legen zu
2020Bourse Zurich: les indices rebondissent pour la première séance de la semaine
2020Aktien Schweiz: Auf Erholungskurs - Finanzwerte im Aufwind
2020Bourse Zurich: le rebond se confirme
More news
Analyst Recommendations on INDIVIOR
More recommendations
Chart INDIVIOR
Duration : Period :
Indivior Technical Analysis Chart | INDV | GB00BRS65X63 | MarketScreener
Technical analysis trends INDIVIOR
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 2,88 $
Last Close Price 1,77 $
Spread / Highest target 147%
Spread / Average Target 62,9%
Spread / Lowest Target 20,2%
EPS Revisions
Managers and Directors
NameTitle
Mark Crossley Executive Director, CEO & COO
Graham C. Hetherington Chairman
Ryan Preblick Chief Financial Officer & Executive Director
Christian Heidbreder Chief Scientific Officer
A. Thomas McLellan Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
INDIVIOR19.30%1 297
MERCK KGAA6.06%78 444
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD5.98%26 402
KYOWA KIRIN CO., LTD.1.49%14 767
BETTA PHARMACEUTICALS CO., LTD.17.07%7 820
YUHAN CORPORATION-3.33%4 098